Catalysts for Postsurgical Therapeutics Inc
12 tracked
Feb 25, 2026
approval
EVEROLIMUS — FDA approval
Postsurgical Therapeutics Inc
→
Feb 13, 2026
device pma
Abbott Vascular — XIENCE Alpine Everolimus Eluting Coronary Stent System; XIENCE Sierra Everolimus Eluting Coronary Stent System; XIENCE P (PMA supplement)
Postsurgical Therapeutics Inc
→
Feb 5, 2026
device pma
Abbott Vascular — XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Stent (PMA supplement)
Postsurgical Therapeutics Inc
→
Feb 3, 2026
device pma
Abbott Vascular — XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine), XIENCE Sierra Everolimus Eluting Coronary Stent (PMA supplement)
Postsurgical Therapeutics Inc
→
Oct 30, 2025
approval
EVEROLIMUS — FDA approval
Postsurgical Therapeutics Inc
→
Oct 22, 2025
device pma
Abbott Vascular — XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine OTW) (PMA supplement)
Postsurgical Therapeutics Inc
→
Sep 26, 2025
device pma
ABBOTT MEDICAL — Esprit BTK Everolimus Eluting Resorbable Scaffold System (PMA supplement)
Postsurgical Therapeutics Inc
→
Aug 29, 2025
device pma
ABBOTT MEDICAL — Esprit BTK Everolimus Eluting Resorbable Scaffold System (PMA supplement)
Postsurgical Therapeutics Inc
→
Aug 16, 2025
device pma
Abbott Vascular — XIENCE Alpine Everolimus Eluting Coronary Stent System (XIENCE Alpine); XIENCE Sierra Everolimus Eluting Coronary Sten (PMA supplement)
Postsurgical Therapeutics Inc
→
Aug 8, 2025
device pma
ABBOTT MEDICAL — Esprit BTK Everolimus Eluting Resorbable Scaffold System (PMA supplement)
Postsurgical Therapeutics Inc
→
Jul 25, 2025
device pma
ABBOTT MEDICAL — Esprit BTK Everolimus Eluting Resorbable Scaffold System (PMA supplement)
Postsurgical Therapeutics Inc
→
Jun 27, 2025
device pma
ABBOTT MEDICAL — Esprit BTK Everolimus Eluting Resorbable Scaffold System (PMA supplement)
Postsurgical Therapeutics Inc
→